KR20120068001A - Ｓ-아데노실메티오닌 제제의 향상된 약물동력학 - Google Patents

Ｓ-아데노실메티오닌 제제의 향상된 약물동력학 Download PDF

Info

Publication number
KR20120068001A
KR20120068001A KR1020127005234A KR20127005234A KR20120068001A KR 20120068001 A KR20120068001 A KR 20120068001A KR 1020127005234 A KR1020127005234 A KR 1020127005234A KR 20127005234 A KR20127005234 A KR 20127005234A KR 20120068001 A KR20120068001 A KR 20120068001A
Authority
KR
South Korea
Prior art keywords
same
composition
formulation
approximately
max
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127005234A
Other languages
English (en)
Korean (ko)
Inventor
아이 데이비드 맥도널드
낸시 해리슨
아니코 타칵스-콕스
로버트 밀러
Original Assignee
메틸레이션 사이언시즈 인터내셔널 에스알엘
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메틸레이션 사이언시즈 인터내셔널 에스알엘 filed Critical 메틸레이션 사이언시즈 인터내셔널 에스알엘
Publication of KR20120068001A publication Critical patent/KR20120068001A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
KR1020127005234A 2009-07-28 2010-07-29 Ｓ-아데노실메티오닌 제제의 향상된 약물동력학 Ceased KR20120068001A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22918609P 2009-07-28 2009-07-28
PCT/IB2010/001879 WO2011012990A2 (en) 2009-07-28 2010-07-29 Improved pharmacokinetics of s-adenosylmethionine formulations

Publications (1)

Publication Number Publication Date
KR20120068001A true KR20120068001A (ko) 2012-06-26

Family

ID=43527262

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127005234A Ceased KR20120068001A (ko) 2009-07-28 2010-07-29 Ｓ-아데노실메티오닌 제제의 향상된 약물동력학

Country Status (9)

Country Link
US (6) US8329208B2 (enExample)
EP (1) EP2464358B1 (enExample)
JP (1) JP2013505897A (enExample)
KR (1) KR20120068001A (enExample)
CN (1) CN102724971A (enExample)
AU (1) AU2010277302B2 (enExample)
CA (1) CA2769490C (enExample)
IN (1) IN2012DN01572A (enExample)
WO (1) WO2011012990A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150143430A (ko) * 2013-04-05 2015-12-23 라이온 가부시키가이샤 내복 조성물
KR20200093132A (ko) 2019-01-28 2020-08-05 이청용 다층구조의 태양광 led조명등과 해충유인 솔라백이 구비된 끈끈이 해충 포획 및 야생동물 퇴치 트랩
KR20210112965A (ko) 2020-03-07 2021-09-15 이청용 우수가림막과 다층구조의 태양광 엘이디조명등이 구비된 끈끈이 해충 포획 및 야생동물 퇴치 트랩
KR102763656B1 (ko) 2024-06-10 2025-02-07 경상북도(농업기술원) 해충 개체정보 모니터링용 포충 트랩장치

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110027342A1 (en) * 2009-07-28 2011-02-03 Msi Methylation Sciences, Inc. S-adenosylmethionine formulations with enhanced bioavailability
US8329208B2 (en) 2009-07-28 2012-12-11 Methylation Sciences International Srl Pharmacokinetics of S-adenosylmethionine formulations
US20130064889A1 (en) * 2011-09-13 2013-03-14 Aptapharma, Inc. Tablet-in-tablet Palperidone Formulations and Methods for Production and Use Thereof
EP2753336B1 (en) * 2012-10-17 2015-05-06 Methylation Sciences International SRL Compositions comprising s-adenosylmethionine and a gallic acid ester
CN105025888B (zh) * 2013-02-22 2018-10-12 志瑞亚新药工业株式会社 肠溶片
US9492535B2 (en) 2013-03-14 2016-11-15 Aimmune Therapeutics, Inc. Peanut formulations and uses thereof
JP6752140B2 (ja) 2013-03-14 2020-09-09 アイミューン セラピューティクス，インコーポレイテッド 経口脱感作のための落花生処方物の製造
EP3030682B1 (en) 2013-08-05 2020-06-03 Twist Bioscience Corporation De novo synthesized gene libraries
ITMI20131906A1 (it) 2013-11-18 2015-05-19 Gnosis Spa Composizioni solide orali a lento rilascio
CA2975852A1 (en) 2015-02-04 2016-08-11 Twist Bioscience Corporation Methods and devices for de novo oligonucleic acid assembly
US9981239B2 (en) 2015-04-21 2018-05-29 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
JP6982362B2 (ja) 2015-09-18 2021-12-17 ツイスト バイオサイエンス コーポレーション オリゴ核酸変異体ライブラリーとその合成
KR20250053972A (ko) 2015-09-22 2025-04-22 트위스트 바이오사이언스 코포레이션 핵산 합성을 위한 가요성 기판
EP3384077A4 (en) 2015-12-01 2019-05-08 Twist Bioscience Corporation FUNCTIONALIZED SURFACES AND MANUFACTURE THEREOF
EP3500672A4 (en) 2016-08-22 2020-05-20 Twist Bioscience Corporation NOVO SYNTHESIZED NUCLEIC ACID BANKS
WO2018057526A2 (en) 2016-09-21 2018-03-29 Twist Bioscience Corporation Nucleic acid based data storage
EP3554514A4 (en) 2016-12-16 2020-08-05 Twist Bioscience Corporation BANKS OF VARIANTS OF IMMUNOLOGICAL SYNAPSE AND THEIR SYNTHESIS
WO2018156792A1 (en) 2017-02-22 2018-08-30 Twist Bioscience Corporation Nucleic acid based data storage
US10894959B2 (en) 2017-03-15 2021-01-19 Twist Bioscience Corporation Variant libraries of the immunological synapse and synthesis thereof
WO2018231864A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
SG11201912057RA (en) 2017-06-12 2020-01-30 Twist Bioscience Corp Methods for seamless nucleic acid assembly
JP2020536504A (ja) 2017-09-11 2020-12-17 ツイスト バイオサイエンス コーポレーション Ｇｐｃｒ結合タンパク質およびその合成
GB2583590A (en) 2017-10-20 2020-11-04 Twist Bioscience Corp Heated nanowells for polynucleotide synthesis
GB2585506A (en) 2018-01-04 2021-01-13 Twist Bioscience Corp DNA-based digital information storage
CN118957038A (zh) 2018-05-18 2024-11-15 特韦斯特生物科学公司 用于核酸杂交的多核苷酸、试剂和方法
WO2020037151A1 (en) 2018-08-16 2020-02-20 Aimmune Therapeutics, Inc. Peanut oral immunotherapy with maintenance dose
JP2022514645A (ja) 2018-12-20 2022-02-14 アイミューン セラピューティクス，インコーポレイテッド ピーナツ経口免疫療法において投与が欠落した場合の投与スケジュール
CN113692409B (zh) 2018-12-26 2025-01-10 特韦斯特生物科学公司 高度准确的从头多核苷酸合成
JP2022522668A (ja) 2019-02-26 2022-04-20 ツイスト バイオサイエンス コーポレーション 抗体を最適化するための変異体核酸ライブラリ
AU2020229349A1 (en) 2019-02-26 2021-10-14 Twist Bioscience Corporation Variant nucleic acid libraries for GLP1 receptor
CN113966229A (zh) 2019-05-10 2022-01-21 爱沐疗法公司 用于改善花生过敏患者的生活质量的方法
EP3987019A4 (en) 2019-06-21 2023-04-19 Twist Bioscience Corporation Barcode-based nucleic acid sequence assembly
JP2021046375A (ja) * 2019-09-19 2021-03-25 ポッカサッポロフード＆ビバレッジ株式会社 β３アドレナリン受容体活性化剤
EP4034566A4 (en) 2019-09-23 2024-01-24 Twist Bioscience Corporation VARIANT NUCLEIC ACID BANKS FOR CRTH2
CN115023440B (zh) 2019-09-23 2025-09-12 特韦斯特生物科学公司 结合CD3ε的抗体
WO2024238657A2 (en) 2023-05-15 2024-11-21 Bonafide Health, Llc Sleep-improving compositions and methods of use

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE37913B1 (en) * 1972-08-02 1977-11-09 Bioresearch Sas Salt of s-adenosyl-l-methionine
IE39517B1 (en) * 1973-06-27 1978-10-25 Bioresearch Sas Double salts of s-adenosyl-l-methhionine
AR221676A1 (es) * 1974-07-12 1981-03-13 Bioresearch Sas Procedimiento para la preparacion de sales estables sulfonicas y/o sulfuricas de la s-adenosil-l-metionina,particularmente utiles como donadores especificos de metilo para las reacciones bioquimicas de transferencia del grupo ch3;asi como tambien las reacciones fundamentales en el metabolismo lipilico,protilico y glucidico
US5264446A (en) * 1980-09-09 1993-11-23 Bayer Aktiengesellschaft Solid medicament formulations containing nifedipine, and processes for their preparation
US4525345A (en) * 1981-12-24 1985-06-25 Verex Laboratories, Inc. Constant order release, solid dosage indomethacin formulation and method of treating arthritis and other inflammatory conditions
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4556678A (en) * 1982-06-24 1985-12-03 Key Pharmaceuticals, Inc. Sustained release propranolol tablet
DE3435325A1 (de) * 1983-04-09 1986-04-17 Nikken Chemicals Co., Ltd., Tokio/Tokyo Langzeitwirkende theophyllin-tablette und verfahren zu deren herstellung
IT1169772B (it) 1983-08-24 1987-06-03 Bioresearch Spa Composizioni terapeutiche per uso orale contenenti sali stabili della s-adenosil-l-metionina
US4680323A (en) * 1983-12-01 1987-07-14 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration
US4537772A (en) 1984-05-02 1985-08-27 Merck & Co., Inc. Enhancing absorption of drugs from gastrointestinal tract using acylcarnitines
IT1173992B (it) * 1984-05-16 1987-06-24 Bioresearch Spa Sali stabili della solfo-adenosil-l-metionina (same) particolarmente idonei per uso farmaceutico orale
US4695591A (en) * 1985-03-29 1987-09-22 Schering Corporation Controlled release dosage forms comprising hydroxypropylmethylcellulose
US4601894A (en) * 1985-03-29 1986-07-22 Schering Corporation Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
US4687757A (en) * 1986-03-24 1987-08-18 Phillips Petroleum Company Hydrofining catalyst composition and process for its preparation
US4756911A (en) * 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
US5200193A (en) * 1987-04-22 1993-04-06 Mcneilab, Inc. Pharmaceutical sustained release matrix and process
US4968509A (en) * 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
US5073380A (en) * 1987-07-27 1991-12-17 Mcneil-Ppc, Inc. Oral sustained release pharmaceutical formulation and process
FR2623396B1 (fr) 1987-11-25 1990-03-30 Sanofi Sa Utilisation de l'ademetionine contre le vieillissement de la peau
US5169642A (en) * 1988-06-24 1992-12-08 Abbott Laboratories Sustained-release drug dosage units
IT1229477B (it) 1989-03-13 1991-09-03 Bioresearch Spa Impiego di 5' deossi - 5' metiltioadenosina, s adenosilmetionina e dei loro sali per la preparazione di composizioni farmaceutiche atte a ridurre la seborrea e composizioni farmaceutiche relative
US5137712A (en) 1990-08-31 1992-08-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of s-adenosyl-l-methionine (SAMe) to reverse and/or prevent supersensitivity, tolerance and extrapyramidal side effects induced by neuroleptic treatment
IT1243859B (it) * 1990-10-23 1994-06-28 Bioresearch Spa Composizioni farmaceutiche comprendenti associazioni fra sali di s-adenosil-l-metionina e acido 5-metil (o 5-formil)-tetraidrofolico per la terapia di complicanze neurologiche negli ammalati di aids.
US5543154A (en) * 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
IL104192A (en) * 1992-02-17 1998-01-04 Siegfried Ag Pharma Pharmaceutical dosage forms having prolonged release rate of zero order of the active ingredient
EP1221615A2 (en) * 1995-04-25 2002-07-10 Oridigm Corporation S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy
DE19631085A1 (de) * 1996-08-01 1998-02-05 Basf Ag Verwendung von (Meth)acrylsäure-Maleinsäure-Copolymeren zur Verbesserung der Permeabilität der Schleimhaut
DE19631084A1 (de) * 1996-08-01 1998-02-05 Basf Ag Verwendung von (Meth)acrylsäure-Copolymeren zur Erhöhung der Permeabilität der Schleimhaut
US5922341A (en) * 1997-10-28 1999-07-13 Vivus, Incorporated Local administration of pharmacologically active agents to treat premature ejaculation
CA2321565C (en) 1998-02-27 2014-10-14 Nutramax Laboratories, Inc. L-ergothioneine, milk thistle, and s-adenosylmethionine for the prevention, treatment and repair of liver damage
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
US7906153B2 (en) 1998-04-08 2011-03-15 Theta Biomedical Consulting & Development Co., Inc. Anti-inflammatory compositions for treating multiple sclerosis
US7060479B2 (en) * 1999-12-08 2006-06-13 Serono Genetics Institute, S.A. Full-length human cDNAs encoding potentially secreted proteins
DE19839443A1 (de) 1998-08-29 2000-03-02 Miklos Ghyczy Arnzneimittel mit entzündungshemmender Wirkung
ATE400251T1 (de) * 1999-02-09 2008-07-15 Pfizer Prod Inc Zusammensetzungen basischer arzneistoffe mit verbesserter bioverfügbarkeit
ES2310164T3 (es) * 1999-02-10 2009-01-01 Pfizer Products Inc. Dispositivo de liberacion controlada por la matriz.
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6685928B2 (en) 1999-12-07 2004-02-03 Rutgers, The State University Of New Jersey Therapeutic compositions and methods
MXPA02009924A (es) * 2000-04-07 2004-08-19 Univ Texas Composiones unicas de fosfolipidos de ion anfoterico y bisfosfonatos y uso de las composiciones como sistemas de suministro de bisfosfato con toxicidad gi reducida.
WO2002049637A1 (en) 2000-12-18 2002-06-27 Orchid Chemicals And Pharmaceuticals Limited A novel soft-gelatin capsule comprising s-adenosylmethionine and a method for producing the same
US6759395B2 (en) * 2000-12-18 2004-07-06 Orchid Chemicals & Pharmaceuticals, Ltd. Soft-gelatin capsule comprising S-adenosylmethionine and a method for producing the same
GB0109428D0 (en) 2001-04-17 2001-06-06 Process & Ind Design Consultan Therapeutic compositions
GB0111579D0 (en) 2001-05-11 2001-07-04 Holford & Associates Ltd Oral supplement
JP3908513B2 (ja) 2001-11-19 2007-04-25 日本甜菜製糖株式会社 肝機能改善剤
EP1499300B1 (en) * 2002-04-29 2009-03-18 Supernus Pharmaceuticals, Inc. Pharmaceutical formulations with improved bioavailability
US7977049B2 (en) * 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
MXPA06003454A (es) * 2003-09-26 2006-08-31 Johnson & Johnson Formulaciones de liberacion controlada de analgesicos opioides y no opiodes.
JP5069001B2 (ja) * 2003-10-10 2012-11-07 ベロクシス ファーマシューティカルズ エー／エス フィブラートを含む固体投与形態
US20050163841A1 (en) * 2003-10-31 2005-07-28 Wong Patrick S. Compositions and dosage forms for enhanced absorption of 3-amino-n-butyl-phosphinic acid
EP1701705A4 (en) 2003-12-24 2007-08-08 Advancis Pharmaceutical Corp IMPROVED ABSORPTION OF DOSAGE FORMS WITH MODIFIED RELEASE
US20050191349A1 (en) * 2003-12-31 2005-09-01 Garth Boehm Galantamine formulations
US7429569B2 (en) * 2004-01-29 2008-09-30 Fast Balance, Inc. Compositions and methods for the regulation of homocysteine levels within the body
US20050181047A1 (en) 2004-02-18 2005-08-18 Jaime Romero Compositions and methods for timed release of water-soluble nutritional supplements
US20080020041A1 (en) 2004-10-19 2008-01-24 Ayres James W Enteric Coated Compositions that Release Active Ingredient(s) in Gastric Fluid and Intestinal Fluid
US20060127506A1 (en) * 2004-12-10 2006-06-15 Hebert Rolland F Compositions of S-adenosyl-L-methionine
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
WO2006079212A1 (en) 2005-01-26 2006-08-03 Diamedica Inc. Use of s-adenosylmethionme, vitamin e, and vitamin c for the treatment of oxidative liver injury or insulin resistance
DE102005024614A1 (de) 2005-05-25 2006-11-30 Röhm Gmbh Verwendung von Polymermischungen zur Herstellung von überzogenen Arzneiformen sowie Arzneiform mit polymerem Mischüberzug
PT1731596E (pt) 2005-06-09 2013-05-10 Gnosis Spa Células de saccharomyces cerevisiae secas, liofilizadas e/ou microencapsuladas com um teor elevado de (s)-(+)-s-adenosill- metionina
NZ561375A (en) 2005-06-27 2011-06-30 Biovail Lab Int Srl Bupropion hydrobromide, and crystalline forms, compositions, and uses of this compound
BRPI0707616A2 (pt) * 2006-02-09 2011-05-10 Alba Therapuetics Corp formulaÇÕes para um efetor de junÇço oclusiva
TW200738269A (en) * 2006-02-09 2007-10-16 Univ Maryland Oral delivery of therapeutic agents using tight junction agonists
ITMI20060629A1 (it) * 2006-03-31 2007-10-01 Daniele Giovannone Composizioni solide orali a base di s-adenosilmetionina e processo per il loro ottenimento
US20100062073A1 (en) 2006-11-29 2010-03-11 Ronald Arthur Beyerinck Pharmaceutical compositions comprising nanoparticles comprising enteric polymers casein
US20090088404A1 (en) * 2007-01-31 2009-04-02 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
US20090197824A1 (en) * 2008-01-31 2009-08-06 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
AU2008210327B2 (en) * 2007-01-31 2011-06-16 Methylation Sciences International Srl Extended release pharmaceutical formulations of S-adenosylmethionine
US20080279931A1 (en) * 2007-05-09 2008-11-13 Northern Holdings Inc. Composition for treatment of pain
ITMI20081405A1 (it) 2008-07-29 2010-01-30 Velleja Res Srl Formulazioni orali istantanee, gelificanti a temperatura ambiente, utili per contrastare il deperimento organico e la sindrome depressiva connessi a cachessia, anoressia, malattia metabolica, malattia endocrina e disfagia
WO2010027014A1 (ja) 2008-09-04 2010-03-11 株式会社カネカ Ｓ－アデノシル－ｌ－メチオニンの吸収性を高める方法およびｓ－アデノシル－ｌ－メチオニンの吸収性が高められた組成物
EP2193787A1 (en) 2008-12-02 2010-06-09 Giorgio Stramentinoli Formulations for systemic buccal delivery comprising s-adenosylmethionine, their preparation and use
US8329208B2 (en) 2009-07-28 2012-12-11 Methylation Sciences International Srl Pharmacokinetics of S-adenosylmethionine formulations
US20110027342A1 (en) 2009-07-28 2011-02-03 Msi Methylation Sciences, Inc. S-adenosylmethionine formulations with enhanced bioavailability

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150143430A (ko) * 2013-04-05 2015-12-23 라이온 가부시키가이샤 내복 조성물
KR20200093132A (ko) 2019-01-28 2020-08-05 이청용 다층구조의 태양광 led조명등과 해충유인 솔라백이 구비된 끈끈이 해충 포획 및 야생동물 퇴치 트랩
KR20210112965A (ko) 2020-03-07 2021-09-15 이청용 우수가림막과 다층구조의 태양광 엘이디조명등이 구비된 끈끈이 해충 포획 및 야생동물 퇴치 트랩
KR102763656B1 (ko) 2024-06-10 2025-02-07 경상북도(농업기술원) 해충 개체정보 모니터링용 포충 트랩장치

Also Published As

Publication number Publication date
WO2011012990A2 (en) 2011-02-03
AU2010277302B2 (en) 2014-06-05
US20140370108A1 (en) 2014-12-18
CA2769490C (en) 2014-04-01
US20160361339A1 (en) 2016-12-15
WO2011012990A3 (en) 2011-06-16
US9931356B2 (en) 2018-04-03
US8865203B2 (en) 2014-10-21
US8329208B2 (en) 2012-12-11
JP2013505897A (ja) 2013-02-21
US20110027360A1 (en) 2011-02-03
CN102724971A (zh) 2012-10-10
US20130129792A1 (en) 2013-05-23
AU2010277302A1 (en) 2012-03-15
US8580296B2 (en) 2013-11-12
US20190060345A1 (en) 2019-02-28
EP2464358A2 (en) 2012-06-20
CA2769490A1 (en) 2011-02-03
WO2011012990A8 (en) 2011-04-28
US20130149350A1 (en) 2013-06-13
EP2464358B1 (en) 2015-06-17
IN2012DN01572A (enExample) 2015-06-05

Similar Documents

Publication Publication Date Title
US9931356B2 (en) Pharmacokinetics of S-adenosylmethionine formulations
US20220273668A1 (en) Irak4 degraders and uses thereof
JP6280535B2 (ja) Ｓ−アデノシルメチオニンおよび没食子酸エステルを含む組成物
JP2013505896A (ja) 生物学的利用能が増強されたｓ−アデノシルメチオニン製剤
KR20210136081A (ko) 화합물의 제제 및 그의 용도
KR102690703B1 (ko) 소듐 페닐부티레이트를 포함하는 맛우수한 조성물 및 그의 용도
KR102224087B1 (ko) 지효성 고체 경구용 조성물
EP2266579A1 (en) Pharmaceutical composition comprising elvucitavine
CN102648915B (zh) 一种治疗或预防神经病理性疼痛的药物组合物
KR20190046675A (ko) 간질환 예방 또는 치료용 의약 조성물
HK1167317A1 (en) Improved pharmacokinetics of s-adenosylmethionine formulations
HK1167317B (en) Improved pharmacokinetics of s-adenosylmethionine formulations
AU2013204928A1 (en) Improved pharmacokinetics of S-Adenosylmethionine formulations
TW202313072A (zh) 檸檬酸鐵之兒科調配物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120228

Patent event code: PA01051R01D

Comment text: International Patent Application

A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20120312

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130905

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20140425

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20130905

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20140425

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20131205

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20120312

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20140626

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20140528

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20140425

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20131205

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20130905

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20120312